The FDA Advisory Panel punted on its assessment of LIRAGLUTIDE with the deciding voter making the decision to "abstain". Animal studies of this medication, in the incretin mimetic class, had shown thyroid C cell tumors in rodents.
Novo however argued that although liraglutude spurs tumor growth in rodent cells, there is no comparable reaction in humans.
We'll see what the FDA decides at some time in the future. In the meantime, I doubt I'll get to "abstain" on any decision I make in the office today.